Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Dose and Single Subcutaneous Dose of BI 655130 in Healthy Japanese Male Volunteers (Double-blind, Randomised, Placebo-controlled Design).
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs BI 655130 (Primary) ; BI 655130 (Primary)
- Indications Pustular psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 30 May 2017 Status changed from not yet recruiting to recruiting.
- 24 Apr 2017 New trial record